Asia Pacific Lung Cancer Therapy Market Forecast to 2030
Asia Pacific Lung Cancer Therapy Market Forecast to 2030 – Regional Analysis – By Therapy Type (Noninvasive and Minimally Invasive), Indication (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), and End User (Hospitals, Oncology Clinics, Research Centers, and Others)
$2,840 – $4,440
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Increase in Cases of Lung Cancer Drive Asia Pacific Lung Cancer Therapy Market
Lung cancer is among the main causes of mortality across the world. This type of cancer can be treated more effectively if it is diagnosed early. Therefore, people at a high risk of lung cancer need to undergo routine testing to detect the formation of cancerous growth inside their lungs. Globally lung cancer is the most common cancer in men and the second most common cancer in women. According to the World Health Organization (WHO), lung cancer is the leading cause of cancer-related deaths globally, in both men and women. As per the World Cancer Research Fund International, ~2.2 million new lung cancer cases were registered worldwide in 2020. As per the Cancer Australia 2023 report, ~14,529 new lung cancer cases were diagnosed in 2022; 7,707 were males and 6,822 were females. Nearly 9% of registered new cancer cases were diagnosed in 2022, with an estimated 8,664 deaths from lung cancer. Also, according to studies from the Indian Council of Medical (ICMR), the number of lung cancer cases in India is expected to increase by more than seven times by 2025 when compared to the same period a decade earlier. Thus, the rising incidence of lung cancer worldwide is contributing to the research and development activities for lung cancer therapy, which is, in turn, driving the market growth.
Asia Pacific Lung Cancer Therapy Market Overview
China has experienced the increasing prevalence of lung cancer over the past few years owing to the various factors including smoking, tobacco consumption, and others. As per the International Agency for Research on Cancer reported that approximately 820,000 new lung cancer diagnoses and 715,000 lung cancer-related deaths occurred in China in 2020. A few of the primary causes of lung cancer in China include tobacco use, radiation exposure, family history, and the presence of chronic lung diseases. Further, image-guided percutaneous lung ablation has proven to be an effective alternative approach for the treatment of lung cancer and other lung malignancies.
Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Lung Cancer Therapy Market Segmentation
The Asia Pacific lung cancer therapy market is segmented based on therapy type, indication, end user, and country.
Based on therapy type, the Asia Pacific lung cancer therapy market is bifurcated into noninvasive and minimally invasive. The noninvasive segment held a larger share in 2022. The minimally invasive segment is further subsegmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others.
By indication, the Asia Pacific lung cancer therapy market is bifurcated into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment held a larger share in 2022.
By end user, the Asia Pacific lung cancer therapy market is segmented into hospitals, oncology clinics, research centers, and others. The hospitals segment held the largest share in 2022.
Based on country, the Asia Pacific lung cancer therapy market is segmented into China, Japan, India, Australia, South Korea, Southeast Asia, and the Rest of Asia Pacific. China dominated the Asia Pacific lung cancer therapy market in 2022.
Medtronic Plc, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Olympus Corp, Meiji Seika Pharma Co Ltd, and Advanz Pharma Corp are some of the leading companies operating in the Asia Pacific lung cancer therapy market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the Asia Pacific lung cancer therapy market was valued at US$ 3,778.03 million in 2022 and is expected to reach US$ 10,963.26 million by 2030, registering a CAGR of 14.2% from 2022 to 2030. Government initiatives for screening and treatment of lung cancer and increase in cases of lung cancer are among the critical factors attributed to the Asia Pacific lung cancer therapy market expansion.
According to an article published by Johnson & Johnson, lung cancer is a leading cause of cancer mortality in the world, and it is generally detected in the later stages. In the initial stages, people with lung cancer show no prominent symptoms, and therefore, in almost 50% of the detected cases, cancer has already reached the metastasis stage. In response to the seriousness of this condition, governments of various countries are focusing on introducing initiatives for encouraging early detection and screening, followed by providing early treatment for lung cancer. In July 2021, Cancer Australia partnered with the Department of Health and Aged Care to evaluate the feasibility of a lung cancer screening program in Australia. After obtaining positive results of the feasibility assessment, in May 2023, the Department of Health and Aged Care, the Government of Australia, declared an investment of US$ 263.8 million for 2023-2024 for the implementation of the National Lung Cancer Screening Program across the country. Through this program, the Department of Health and Aged Care focuses on the prevention and early detection of lung cancer. Thus, an upsurge in initiatives taken by governments for the early detection and proper treatment of lung cancer patients fuels the growth of the Asia Pacific lung cancer therapy market.
On the contrary, high cost of lung cancer therapy hampers the growth of Asia Pacific lung cancer therapy market.
Based on therapy type, the Asia Pacific lung cancer therapy market is bifurcated into noninvasive and minimally invasive. The noninvasive segment held 81.6% share of the Asia Pacific lung cancer therapy market in 2022, amassing US$ 3,082.64 million. It is projected to garner US$ 8,807.00 million by 2030 to expand at 14.0% CAGR during 2022-2030. The minimally invasive segment is further subsegmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others.
By indication, the Asia Pacific lung cancer therapy market is bifurcated into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment held 87.4% share of the Asia Pacific lung cancer therapy market in 2022, amassing US$ 3,300.95 million. It is projected to garner US$ 9,668.47 million by 2030 to expand at 14.4% CAGR during 2022-2030.
By end user, the Asia Pacific lung cancer therapy market is segmented into hospitals, oncology clinics, research centers, and others. The hospitals segment held 50.7% share of the Asia Pacific lung cancer therapy market in 2022, amassing US 1,917.08 million. It is projected to garner US$ 5,421.82 million by 2030 to expand at 13.9% CAGR during 2022-2030.
Based on country, the Asia Pacific lung cancer therapy market is segmented into China, Japan, India, Australia, South Korea, Southeast Asia, and the Rest of Asia Pacific. China held 23.4% share of Asia Pacific lung cancer therapy market in 2022, amassing US$ 882.93 million. It is projected to garner US$ 2,527.03 million by 2030 to expand at 14.0% CAGR during 2022-2030.
Key players operating in the Asia Pacific lung cancer therapy market are Medtronic Plc, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Olympus Corp, Meiji Seika Pharma Co Ltd, and Advanz Pharma Corp, among others.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific lung cancer therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the lung cancer therapy market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Asia Pacific Lung Cancer Therapy Market, by Country
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Lung Cancer Therapy Market – Key Industry Dynamics
4.1 Market Drivers:
4.1.1 Increase in Cases of Lung Cancer
4.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
4.2 Market Restraints
4.2.1 High Cost of Lung Cancer Therapy
4.3 Market Opportunities
4.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
4.4 Future Trends
4.4.1 Growing Demand for Targeted Therapy
4.5 Impact Analysis:
5. Lung Cancer Therapy Market – Asia Pacific Market Analysis
5.1 Asia Pacific Lung Cancer Therapy Market Revenue (US$ Mn), 2020 – 2030
6. Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by Therapy Type
6.1 Overview
6.2 Asia Pacific Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
6.3 Non-Invasive Therapy
6.3.1 Overview
6.3.2 Non-Invasive Therapy: Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Minimally Invasive
6.4.1 Overview
6.4.2 Minimally Invasive: Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
6.4.3 Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
7. Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by Indication
7.1 Overview
7.2 Asia Pacific Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
7.3 Non-Small Cell Lung Cancer
7.3.1 Overview
7.3.2 Non-Small Cell Lung Cancer: Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Small Cell Lung Cancer
7.4.1 Overview
7.4.2 Small Cell Lung Cancer: Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by End User
8.1 Overview
8.2 Asia Pacific Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
8.3 Hospitals
8.3.1 Overview
8.3.2 Hospitals: Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Oncology Clinics
8.4.1 Overview
8.4.2 Oncology Clinics: Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Research Centers
8.5.1 Overview
8.5.2 Research Centers: Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Lung Cancer Therapy Market – Country Analysis
9.1.1 Asia Pacific Asia Pacific Lung Cancer Therapy Market, by Country
9.1.1.1 China
9.1.1.1.1 Overview
9.1.1.1.2 China: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.1.3 China: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.1.3.1 China: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.1.4 China: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.1.5 China: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.2 Japan
9.1.1.2.1 Overview
9.1.1.2.2 Japan: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.2.3 Japan: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.2.3.1 Japan: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.2.4 Japan: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.2.5 Japan: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.3 India
9.1.1.3.1 Overview
9.1.1.3.2 India Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.3.3 India: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.3.3.1 India: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.3.4 India: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.3.5 India: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.4 Australia
9.1.1.4.1 Overview
9.1.1.4.2 Australia: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.4.3 Australia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.4.3.1 Australia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.4.4 Australia: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.4.5 Australia: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.5 South Korea
9.1.1.5.1 Overview
9.1.1.5.2 South Korea: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.5.3 South Korea: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.5.3.1 South Korea: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.5.4 South Korea: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.5.5 South Korea: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.6 Southeast Asia
9.1.1.6.1 Overview
9.1.1.6.2 Southeast Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.6.3 Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.6.3.1 Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.6.4 Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.6.5 Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.6.6 Singapore
9.1.1.6.6.1 Singapore: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.6.6.2 Singapore: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.6.6.2.1 Singapore: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.6.6.3 Singapore: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.6.6.4 Singapore: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.6.7 Malaysia
9.1.1.6.7.1 Malaysia: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.6.7.2 Malaysia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.6.7.2.1 Malaysia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.6.7.3 Malaysia: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.6.7.4 Malaysia: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.6.8 Indonesia
9.1.1.6.8.1 Indonesia: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.6.8.2 Indonesia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.6.8.2.1 Indonesia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.6.8.3 Indonesia: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.6.8.4 Indonesia: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.6.9 Vietnam
9.1.1.6.9.1 Vietnam: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.6.9.2 Vietnam: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.6.9.2.1 Vietnam: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.6.9.3 Vietnam: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.6.9.4 Vietnam: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.6.10 Cambodia
9.1.1.6.10.1 Cambodia: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.6.10.2 Cambodia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.6.10.2.1 Cambodia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.6.10.3 Cambodia: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.6.10.4 Cambodia: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.6.11 Philippines
9.1.1.6.11.1 Philippines: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.6.11.2 Philippines: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.6.11.2.1 Philippines: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.6.11.3 Philippines: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.6.11.4 Philippines: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.6.12 Rest of Southeast Asia
9.1.1.6.12.1 Rest of Southeast Asia: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.6.12.2 Rest of Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.6.12.2.1 Rest of Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.6.12.3 Rest of Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.6.12.4 Rest of Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.7 Rest of Asia Pacific
9.1.1.7.1 Overview
9.1.1.7.2 Rest of Asia Pacific: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.7.3 Rest of Asia Pacific: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.7.3.1 Rest of Asia Pacific: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.7.4 Rest of Asia Pacific: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.7.5 Rest of Asia Pacific: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
10. Lung Cancer Therapy Market – Industry Landscape
10.1 Overview
10.2 Growth Strategies in Asia Pacific Lung Cancer Therapy Market
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Medtronic Plc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 RF Medical Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Johnson & Johnson
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Merck KGaA
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Sun Pharmaceutical Industries Ltd
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Bioventus Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Olympus Corp
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Meiji Seika Pharma Co Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Advanz Pharma Corp
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Lung Cancer Therapy Market Segmentation
Table 2. Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 3. China: Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 4. China: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 5. China: Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 6. China Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 7. Japan Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 8. Japan: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 9. Japan Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 10. Japan: Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 11. India: Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 12. India: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 13. India: Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 14. India: Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 15. Australia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 16. Australia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 17. Australia: Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 18. Australia: Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 19. South Korea: Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 20. South Korea: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 21. South Korea: Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 22. South Korea: Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 23. Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 24. Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 25. Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 26. Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 27. Singapore: Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 28. Singapore: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 29. Singapore: Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 30. Singapore: Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 31. Malaysia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 32. Malaysia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 33. Malaysia: Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 34. Malaysia: Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 35. Indonesia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 36. Indonesia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 37. Indonesia: Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 38. Indonesia: Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 39. Vietnam: Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 40. Vietnam: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 41. Vietnam: Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 42. Vietnam: Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 43. Cambodia Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 44. Cambodia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 45. Cambodia: Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 46. Cambodia: Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 47. Philippines: Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 48. Philippines: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 49. Philippines: Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 50. Philippines: Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 51. Rest of Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 52. Rest of Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 53. Rest of Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 54. Rest of Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 55. Rest of Asia Pacific: Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 56. Rest of Asia Pacific: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 57. Rest of Asia Pacific: Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 58. Rest of Asia Pacific: Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 59. Recent Inorganic Growth Strategies in the Asia Pacific Lung Cancer Therapy Market
Table 60. Recent Organic Growth Strategies in Asia Pacific Lung Cancer Therapy Market
Table 61. Glossary of Terms, Asia Pacific Lung Cancer Therapy Market
LIST OF FIGURES
Figure 1. Asia Pacific Lung Cancer Therapy Market Segmentation, By Country
Figure 2. Asia Pacific Lung Cancer Therapy Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Lung Cancer Therapy Market Revenue (US$ Mn), 2020 – 2030
Figure 5. Asia Pacific Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
Figure 6. Non-Invasive Therapy: Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Minimally Invasive: Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Asia Pacific Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 9. Non-Small Cell Lung Cancer: Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Small Cell Lung Cancer: Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Asia Pacific Lung Cancer Therapy Market Revenue Share, End User, 2022 & 2030 (%)
Figure 12. Hospitals: Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Oncology Clinics: Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Research Centers: Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Asia Pacific Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Asia Pacific Asia Pacific Lung Cancer Therapy Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 17. Asia Pacific Asia Pacific Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 18. China: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. Japan: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. India: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Australia: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. South Korea: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Southeast: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Singapore: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Malaysia: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Indonesia: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 27. Vietnam: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. Cambodia: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 29. Philippines: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 30. Rest of Southeast Asia: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 31. Rest of Asia Pacific: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 32. Growth Strategies in Asia Pacific Lung Cancer Therapy Market
The List of Companies – Asia Pacific Lung Cancer Therapy Market
1. Advanz Pharma Corp
2. Bioventus Inc
3. Johnson & Johnson
4. Medtronic Plc
5. Meiji Seika Pharma Co Ltd
6. Merck KGaA
7. Olympus Corp
8. RF Medical Co Ltd
9. Sun Pharmaceutical Industries Ltd
You must be logged in to post a review.
Reviews
There are no reviews yet.